What are the Factors that Could Contribute to the Lower Risk of Major Bleeding with Bivalirudin Compared with Unfractionated Heparin for Percutaneous Coronary Intervention?

Ahmed N Mahmoud, Anthony A Bavry, Islam Y Elgendy

Keywords


Anticoagulation; Percutaneous coronary intervention; Coronary artery disease

Full Text:

PDF HTML

References


Palla M, Briasoulis A, Telila T, Kondur A. The effects of bivalirudin vs heparin on short-term outcomes in patients undergoing percutaneous coronary intervention. Int J Cardiol. 2016;214:270-274.

Zhang S, Gao W, Li H, Zou M, Sun S, Ba Y, et al. Efficacy and safety of bivalirudin versus heparin in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Int J Cardiol. 2016; 209: 87-95.

Cavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet. 2014;384:599-606.

Mahmoud AN, Elgendy IY. Bivalirudin versus unfractionated heparin for percutaneous coronary intervention with radial access: A meta-analysis of randomized trials. Int J Cardiol. 2016. DOI. 10.1016/j.ijcard.2016.04.140.

Bavry AA, Elgendy IY, Mahmoud A, Jadhav MP, Huo T. Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials. PLoS One. 2015;10:e0127832.

De Luca G, Navarese EP, Cassetti E, Verdoia M, Suryapranata H. Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy. Am J Cardiol. 2011; 107: 198-203.

Elgendy IY, Huo T, Bhatt DL, Bavry AA. Is aspiration thrombectomy beneficial in patients undergoing primary percutaneous coronary intervention? Meta-Analysis of randomized trials. Circ Cardiovasc Interv. 2015;8:e002258.

Hanna EB, Rao SV, Manoukian SV, Saucedo JF. The evolving role of glycoprotein IIb/IIIa inhibitors in the setting of percutaneous coronary intervention strategies to minimize bleeding risk and optimize outcomes. JACC Cardiovasc Interv. 2010; 3: 1209-19.

Mahmoud A, Saad M, Elgendy AY, Abuzaid A, Elgendy IY. Bivalirudin in percutaneous coronary intervention, is it the anticoagulant of choice? Cardiovasc Ther. 2015;33:227-235.

Shewan LG, Coats AJS, Henein M. Requirements for ethical publishing in biomedical journals. International Cardiovascular Forum Journal 2015;2:2 DOI: 10.17987/icfj.v2i1.4.




DOI: https://doi.org/10.17987/icfj.v9i0.359

Copyright (c) 2017 Ahmed N Mahmoud, Islam Y Elgendy

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.